WEHI-P8

WEHI-P8 is an orally active inhibitor targeting the coronavirus papain-like protease (PLpro) . It inhibits SARS-CoV-2 PLpro with an IC50 of 12 nM and demonstrates excellent cellular activity with an EC50 of 298 nM. Additionally, WEHI-P8 has protective effects in mice against prolonged lung and brain symptoms caused by SARS-CoV-2. This compound is applicable for research on post-COVID-19 syndrome.